Insulin Infusion Pump Market Report 2026

The insulin infusion pump market size has grown rapidly in recent years. It will grow from $6.93 billion in 2025 to $7.64 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to rising prevalence of diabetes globally, limitations of multiple daily insulin injections, advancements in insulin pump technology, increased awareness of intensive insulin therapy, growing adoption of self-monitoring blood glucose.

The insulin infusion pump market size is expected to see rapid growth in the next few years. It will grow to $11.19 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing demand for automated insulin delivery, rising incidence of type 1 and type 2 diabetes, growing adoption of remote patient monitoring, technological advancements in smart insulin pumps, expanding reimbursement coverage for diabetes devices. Major trends in the forecast period include increasing adoption of continuous glucose-guided insulin delivery, rising preference for wearable and tubeless insulin pumps, growing shift toward home-based diabetes management, expansion of closed-loop and hybrid insulin systems, improved patient adherence through simplified insulin delivery.

The rising prevalence of diabetes is expected to drive growth in the insulin infusion pump market in the coming years. Diabetes is a chronic condition in which the body cannot properly regulate blood glucose levels. The increasing prevalence of diabetes is largely driven by sedentary lifestyles and poor dietary habits, leading to obesity, insulin resistance, and higher rates of type 2 diabetes. Insulin infusion pumps support diabetes management by delivering continuous and precise doses of insulin, maintaining stable blood glucose levels. These devices reduce the need for frequent injections, offering convenience and improved glucose control. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported that 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% increase from 3,065,825 cases in 2022. Therefore, the growing prevalence of lifestyle-related diseases is expected to drive market growth for insulin infusion pumps.

Leading companies in the insulin infusion pump market are developing innovative products, such as insulin patch pump systems, to improve convenience, portability, and provide discreet and comfortable insulin delivery options. Insulin patch pump systems are small, wearable devices that deliver insulin through the skin without traditional tubing. For instance, in November 2023, ViCentra BV, a Netherlands-based medical device company, launched a hybrid closed-loop system combining its Kaleido insulin patch pump with the Diabeloop DBLG1 algorithm and Dexcom G6 continuous glucose monitoring. This integrated artificial pancreas automatically adjusts insulin dosing in real time, reducing hypoglycemia and improving glucose control and time in range for patients with type 1 diabetes. The system is user-friendly, requires minimal setup without fingerstick tests, and uploads data to a cloud platform for monitoring by users and healthcare providers.

In May 2023, Medtronic plc, an Ireland-based medical technology company, acquired EOFlow for $738 million. Through this acquisition, Medtronic aims to strengthen its diabetes management portfolio by integrating EOFlow’s wearable insulin delivery technology. EOFlow Co. Ltd. is a South Korea-based medical technology company specializing in the development of wearable and disposable insulin patch pumps to improve diabetes care.

Major companies operating in the insulin infusion pump market are Roche Holding AG, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed Holding AG, Beta Bionics Inc., SOOIL Development Co. Ltd.

North America was the largest region in the insulin infusion pump market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the insulin infusion pump market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insulin infusion pump market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the insulin infusion pump market by increasing costs of electronic components, sensors, and precision manufacturing inputs used in pump production. These effects are most pronounced in smart and closed-loop insulin pump segments, particularly across asia-pacific and europe where reliance on imported components is high. Elevated tariffs have increased device prices for hospitals and home care users. However, tariffs are also encouraging local manufacturing, supply chain diversification, and investment in cost-efficient insulin delivery technologies, supporting long-term market resilience.

The insulin infusion pump market research report is one of a series of new reports that provides insulin infusion pump market statistics, including insulin infusion pump industry global market size, regional shares, competitors with a insulin infusion pump market share, detailed insulin infusion pump market segments, market trends and opportunities, and any further data you may need to thrive in the insulin infusion pump industry. This insulin infusion pump market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An insulin infusion pump is a small, wearable device that provides continuous insulin delivery for individuals with diabetes, helping to maintain optimal blood glucose levels. The device delivers insulin through a catheter placed under the skin, offering more precise and flexible management compared to multiple daily injections.

The main types of insulin infusion pumps include continuous subcutaneous insulin infusion (CSII) pumps, insulin delivery pens, and wearable insulin pumps. CSII pumps deliver a steady, continuous dose of rapid-acting insulin via a small catheter under the skin. Key technologies include remote monitoring systems, closed-loop systems, and smart insulin pumps. These devices are used across various settings, including hospitals, home care environments, and diabetes clinics.

The insulin infusion pump market consists of revenues earned by entities providing services such as bolus insulin delivery, customizable dosing schedules, and blood glucose monitoring integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The insulin infusion pump market also includes sales of tubed insulin pumps, rechargeable and disposable pump units, smart pump controllers, and integrated CGM-compatible devices designed to improve glycemic control in diabetes patients. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.